INTRODUCTION

A pharmaceutical and biotechnology

company headquartered in Mumbai, India.

- Manufacturing plants in India, UK, Ireland, France and US.

-Subsidiaries in US, UK, Ireland and France.

-Founded by Habil Khorakiwala in the early 1960s.

- First company outside of the US and Europe to manufacture

recombinant human insulin.
 SWOT ANALYSIS

STRENGTHS

• Strong expertise in the area of Recombinant

Biotechnology
• Strong presence in the European market (50%+
revenue comes from Europe)
• Significant ramping up of the US business (with a
growth of 50%)
• Robust manufacturing infrastructure
• Strong insulin portfolio in India
WEAKNESSES

• Less contribution towards revenues by the US

business

• High debt burden

OPPORTUNITIES
• Leverage on synergies present in the European
market

• Launch of Glaritus
THREATS

• Integration of European businesses is a major challenge (Negma

and Pinewood acquisitions have to be integrated with the UK
business)
• Pricing pressure in the US may restrict expected revenue
growth (price erosion more than 95%) specially in cephalosporin
segment, with growing competition from companies like Orchid
Chemicals and Lupin
• High competition for EPO in regulated markets
• Increasing competition in the European generic market with the
growing presence of frontline Indian pharma companies including
Ranbaxy and Reddys
 MARKET

• Annual turnover of US$ 650 million, and a market capitalisation

of over $ 1 billion.

• Wockhardt has revenue of Rs 4,501 crore and operating profit

(EBIDTA) at Rs 823 crore during the 15 months period (Jan
2009 – Mar 2010).

• For the quarter (Jan-March 2010) , the sales revenue was Rs 872
crore and operating profit (EBITDA) was Rs 158 crore.
 GROWTH

• India Business:
Wockhardt’s India branded business grew by 24% in Jan-Mar
2010 over the corresponding period of 2009.
• Europe Business:
Wockhardt UK grew by 19% compared to the industry growth
of only 5% in Jan-Mar 2010 over the corresponding period of
2009.
• USA Business:
Wockhardt`s Morton Grove Pharmaceuticals business has
shown a robust 40% growth in Jan-Mar 2010 over the
corresponding period of 2009.
 TOP PRODUCTS

DIABETOLOGY NEPHROLOGY
Wosulin (Recombinant Insulin ) Wepox (Recombinant
Mopaday (Oral Antidiabetic) Erythropoietin)
Glimaday (Oral Antidiabetic)

PAIN MANAGEMENT: NUTRITION

Proxyvon Methycobal
Dexolac
NEURO-PSYCHIATRY
Spasmo-Proxyvon

NEURO-PSYCHIATRY COUGH THERAPY

Libotryp Zedex
Tryptomer Bro-Zedex
Viscodyne
 PRODUCT-WISE VALUES

PRODUCTS Value in Crores % +/- %

Spasmo-Proxyvon 89.41 0.21 7.4

Dexolac 61.99 0.14 26.9

Bro-Zedex 30.38 0.07 36.9

Magenta 30.31 0.07 -1.9

Zedex 28.27 0.07 41

Proxyvon 24.2 0.06 21.4

Merideca 23.5 0.05 -17.5

Wokadine 23.47 0.05 36.8

 NEW LAUNCHES

• Insulin Glaritus
• Tamsulosin capsules(Flomax)
• Amoxicillin Clav K OS,
• Azithromycin Tablets,
• Divalproex Extended Release Tablets
• Midazolam HCI Injection,
• Nicardipine Injection,
• Ranitidine Tablets,
• Risperidone Tablets,
• Ropinirole HCI Tablets
 TOP COMPETITORS

• Aurobindo Pharma Limited

• Cipla Limited
• Glaxo Smithkline Pharmaceuticals Limited
• Dr. Reddy's Laboratories Limited
• Ranbaxy Laboratories Limited